一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

Unlabeled?FXX489?,Unlabeled?FXX489?
  • Unlabeled?FXX489?,Unlabeled?FXX489?

Unlabeled?FXX489? 新品

價(jià)格 詢價(jià)
包裝 1mg 10mg 100mg
最小起訂量 1mg
發(fā)貨地 江西
更新日期 2026-05-09
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱(chēng):Unlabeled?FXX489?英文名稱(chēng):Unlabeled?FXX489?
CAS:3076330-05-4品牌: TanzhenBio
產(chǎn)地: 江西贛州保存條件: -20℃
純度規(guī)格: 98%產(chǎn)品類(lèi)別: 放射顯影多肽產(chǎn)品
別名: Unlabeled?FXX489?貨號(hào): .
靶點(diǎn): Key eligibility criteria include prior treatment for locally advanced unresectable or metastatic disease and having all measurable lesions (per RECIST 1.1) showing [68Ga]Ga-NNS309 uptake on positron emission tomography/computed tomography (PET/CT). Patients who are eligible for treatment receive one dose of [177Lu]Lu-NNS309 on day 1 of each cycle. A 6-week and a 4-week dosing schedule will be explored. Dosimetry data will be obtained from patients in the dose escalation part after the first dose and will be used to calculate the cumulative radiation exposure. Dose escalation will be guided by a Bayesian hierarchical logistic regression model with overdose control (EWOC) principle, and assessment of all relevant data available from all dose levels including safety, tolerability, clinical dosimetry, pharmacodynamics, and preliminary efficacy. Once the recommended dose(s) (RD) and schedule(s) of [177Lu]Lu-NNS309 are determined, the expansion part may open and will include patients with locally advanced or metastatic PDAC (n~20), locally advanced or metastatic NSCLC (n~20), HR+/HER2- ductal BC (n~15), HR+/HER2- lobular BC (n~15), and triple negative BC (; n~24).The primary objectives of the study are to evaluate the safety and tolerability of [177Lu]Lu-NNS309 and to identify the RD(s) and regimen(s) of [177Lu]Lu-NNS309 for further clinical evaluation. Secondary objectives of the study are to evaluate the preliminary anti-tumor activity of [177Lu]Lu-NNS309, characterize the pharmacokinetics of [177Lu]Lu-NNS309 in blood and urine, the radiation dosimetry for organs and tumor lesions, and to evaluate the safety and imaging properties of [68Ga]Ga-NNS309.生物作用: Key eligibility criteria include prior treatment for locally advanced unresectable or metastatic disease and having all measurable lesions (per RECIST 1.1) showing [68Ga]Ga-NNS309 uptake on positron emission tomography/computed tomography (PET/CT). Patients who are eligible for treatment receive one dose of [177Lu]Lu-NNS309 on day 1 of each cycle. A 6-week and a 4-week dosing schedule will be explored. Dosimetry data will be obtained from patients in the dose escalation part after the first dose and will be used to calculate the cumulative radiation exposure. Dose escalation will be guided by a Bayesian hierarchical logistic regression model with overdose control (EWOC) principle, and assessment of all relevant data available from all dose levels including safety, tolerability, clinical dosimetry, pharmacodynamics, and preliminary efficacy. Once the recommended dose(s) (RD) and schedule(s) of [177Lu]Lu-NNS309 are determined, the expansion part may open and will include patients with locally advanced or metastatic PDAC (n~20), locally advanced or metastatic NSCLC (n~20), HR+/HER2- ductal BC (n~15), HR+/HER2- lobular BC (n~15), and triple negative BC (; n~24).The primary objectives of the study are to evaluate the safety and tolerability of [177Lu]Lu-NNS309 and to identify the RD(s) and regimen(s) of [177Lu]Lu-NNS309 for further clinical evaluation. Secondary objectives of the study are to evaluate the preliminary anti-tumor activity of [177Lu]Lu-NNS309, characterize the pharmacokinetics of [177Lu]Lu-NNS309 in blood and urine, the radiation dosimetry for organs and tumor lesions, and to evaluate the safety and imaging properties of [68Ga]Ga-NNS309.
應(yīng)用: Key eligibility criteria include prior treatment for locally advanced unresectable or metastatic disease and having all measurable lesions (per RECIST 1.1) showing [68Ga]Ga-NNS309 uptake on positron emission tomography/computed tomography (PET/CT). Patients who are eligible for treatment receive one dose of [177Lu]Lu-NNS309 on day 1 of each cycle. A 6-week and a 4-week dosing schedule will be explored
2026-05-09 Unlabeled?FXX489? Unlabeled?FXX489? 1mg/RMB;10mg/RMB;100mg/RMB TanzhenBio 江西贛州 -20℃ 98% 放射顯影多肽產(chǎn)品

Key eligibility criteria include prior treatment for locally advanced unresectable or metastatic disease and having all measurable lesions (per RECIST 1.1) showing [68Ga]Ga-NNS309 uptake on positron emission tomography/computed tomography (PET/CT). Patients who are eligible for treatment receive one dose of [177Lu]Lu-NNS309 on day 1 of each cycle. A 6-week and a 4-week dosing schedule will be explored. Dosimetry data will be obtained from patients in the dose escalation part after the first dose and will be used to calculate the cumulative radiation exposure. Dose escalation will be guided by a Bayesian hierarchical logistic regression model with overdose control (EWOC) principle, and assessment of all relevant data available from all dose levels including safety, tolerability, clinical dosimetry, pharmacodynamics, and preliminary efficacy. Once the recommended dose(s) (RD) and schedule(s) of [177Lu]Lu-NNS309 are determined, the expansion part may open and will include patients with locally advanced or metastatic PDAC (n~20), locally advanced or metastatic NSCLC (n~20), HR+/HER2- ductal BC (n~15), HR+/HER2- lobular BC (n~15), and triple negative BC (; n~24).The primary objectives of the study are to evaluate the safety and tolerability of [177Lu]Lu-NNS309 and to identify the RD(s) and regimen(s) of [177Lu]Lu-NNS309 for further clinical evaluation. Secondary objectives of the study are to evaluate the preliminary anti-tumor activity of [177Lu]Lu-NNS309, characterize the pharmacokinetics of [177Lu]Lu-NNS309 in blood and urine, the radiation dosimetry for organs and tumor lesions, and to evaluate the safety and imaging properties of [68Ga]Ga-NNS309.

關(guān)鍵字: 3076330-05-4;

公司簡(jiǎn)介

南昌探真生物技術(shù)有限公司 主要業(yè)務(wù):多肽服務(wù) ,肽核酸合成
成立日期 2019-02-05 (8年) 注冊(cè)資本 300萬(wàn)人民幣
員工人數(shù) 10-50人 年?duì)I業(yè)額 ¥ 100萬(wàn)-300萬(wàn)
主營(yíng)行業(yè) 生物活性小分子,有機(jī)合成試劑,氨基糖苷類(lèi) 經(jīng)營(yíng)模式 貿(mào)易,工廠,試劑,定制,服務(wù)
  • 南昌探真生物技術(shù)有限公司
VIP 7年
  • 公司成立:8年
  • 注冊(cè)資本:300萬(wàn)人民幣
  • 企業(yè)類(lèi)型:生產(chǎn)型
  • 主營(yíng)產(chǎn)品:多肽, 放射顯影化合物
  • 公司地址:江西省南昌市小藍(lán)經(jīng)濟(jì)技術(shù)開(kāi)發(fā)區(qū)匯仁大道266號(hào)18棟1樓
詢盤(pán)

店內(nèi)推薦

Unlabeled?FXX489?相關(guān)廠家報(bào)價(jià)

產(chǎn)品名稱(chēng) 價(jià)格   公司名稱(chēng) 報(bào)價(jià)日期
詢價(jià)
VIP2年
奧夫侖醫(yī)藥(四川)有限公司
2026-06-15
詢價(jià)
VIP1年
江西研肽生物醫(yī)藥科技有限公司
2026-05-09
詢價(jià)
VIP1年
江西輻氨生物技術(shù)有限公司
2026-04-21
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購(gòu)買(mǎi)數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的
主頁(yè) | 企業(yè)會(huì)員服務(wù) | 廣告業(yè)務(wù) | 聯(lián)系我們 | 舊版入口 | 中文MSDS | CAS Index | 常用化學(xué)品CAS列表 | 化工產(chǎn)品目錄 | 新產(chǎn)品列表 |投訴中心
Copyright ? 2008 ChemicalBook 京ICP備07040585號(hào)  京公海網(wǎng)安備110108000080號(hào)  All rights reserved.
济阳县| 灵寿县| 龙游县| 龙口市| 盐亭县| 探索| 珠海市| 天祝| 祁连县| 木里| 都匀市| 德阳市| 扶余县| 巧家县| 菏泽市| 武山县| 武山县| 福州市| 荥经县| 泸西县| 石林| 公安县| 水城县| 屏边| 花莲县| 铁岭市| 舞钢市| 当阳市| 利津县| 宁武县| 澜沧| 灵台县| 湘西| 墨脱县| 新晃| 资兴市| 五家渠市| 信宜市| 民县| 日照市| 胶南市|